Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11794387 | 0.98 | CA1 (0.54) | CA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6934444 | 0.85 | ALDH1A1 (0.44) | CA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6938929 | 0.85 | MAPT (0.50) | CA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6942334 | 0.85 | MAPT (0.50) | CA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6939049 | 0.85 | ALDH1A1 (0.45) | CA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL11705642 | 0.84 | ALDH1A1 (0.44) | CA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6676417 | 0.84 | CA1 (0.43) | CA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6943357 | 0.83 | MAPT (0.46) | CA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6676360 | 0.83 | OPRL1 (0.44) | CA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6937407 | 0.83 | MAPT (0.60) | CA1ALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39530-E1 | 3-amino-3-arylpropan-1-ol-compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2007-03-27 | — | — | US | disclosed |
| US-7012099-B2 | Using substituted 4-amino-1- phenylbutan-2-ol compounds in form of their racemates, enantiomers, diastereoisomers or corresponding bases or corresponding salts of acids as regulators for the nociceptin/orphanin FQ ligands in drugs | GRUENENTHAL GMBH (DE) | 2006-03-14 | — | — | US | disclosed |
| EP-1253917-B1 | USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2005-02-16 | — | — | EP | disclosed |
| EP-1289514-B1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-11-03 | — | — | EP | disclosed |
| EP-1043306-B1 | 3-amino-3-arylpropan-1-ol-derivates, their preparation and use | GRUENENTHAL GMBH (DE) | 2004-03-31 | — | — | EP | disclosed |
| EP-1043307-B1 | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | GRUENENTHAL GMBH (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20030008859-A1 | Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1253917-A2 | USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-6410790-B1 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2002-06-25 | — | — | US | disclosed |
| US-6288278-B1 | BENZENE DERIVED AMINO ALCOHOLS AS DRUGS | GRUENENTHAL GMBH (DE) | 2001-09-11 | — | — | US | disclosed |
| WO-2001047506-A2 | USE OF SUBSTITUTED 4-AMINO-1-PHENYLBUTAN-2-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2001-07-05 | — | — | WO | disclosed |
| EP-1043307-A2 | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | Grünenthal GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| EP-1043306-A2 | 3-amino-3-arylpropan-1-ol-derivates, their preparation and use | Grünenthal GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008859-A1 | Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments | OPRL1, OPRM1, OPRK1 | CA1 4634/4885ALDH1A1 659/4885MAPT 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.